Citius Pharmaceuticals Inc (NASDAQ:CTXR) has a beta value of 1.54 and has seen 112.35 million shares traded in the recent trading session. The company, currently valued at $21.54M, closed the recent trade at $0.14 per share which meant it gained $0.01 on the day or 2.84% during that session. The CTXR stock price is -664.29% off its 52-week high price of $1.07 and 21.43% above the 52-week low of $0.11. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.78 million shares traded. The 3-month trading volume is 1.84 million shares.
The consensus among analysts is that Citius Pharmaceuticals Inc (CTXR) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Sporting 2.84% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CTXR stock price touched $0.14 or saw a rise of 38.86%. Year-to-date, Citius Pharmaceuticals Inc shares have moved -81.81%, while the 5-day performance has seen it change -38.63%. Over the past 30 days, the shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) have changed -62.20%. Short interest in the company has seen 11.79 million shares shorted with days to cover at 13.22.
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
Figures show that Citius Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -78.22% over the past 6 months, with this year growth rate of -8.33%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
3 have an estimated revenue figure of 7.06M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 28.21% over the past 5 years.
CTXR Dividends
Citius Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Insiders own 6.37% of the company shares, while shares held by institutions stand at 12.36% with a share float percentage of 13.20%. Investors are also buoyed by the number of investors in a company, with Citius Pharmaceuticals Inc having a total of 66.0 institutions that hold shares in the company. The top two institutional holders are ARMISTICE CAPITAL, LLC with over 10.16 million shares worth more than $5.93 million. As of 2024-06-30, ARMISTICE CAPITAL, LLC held 6.3845% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.33 million shares as of 2024-06-30. The firm’s total holdings are worth over $3.69 million and represent 3.9776% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Jun 30, 2024, the former fund manager holds about 22.35% shares in the company for having 4.14 shares of worth $0.59 million while later fund manager owns 1.96 shares of worth $0.28 million as of Jun 30, 2024, which makes it owner of about 10.57% of company’s outstanding stock.
